Data protection Impressum

Pharma

Lausanne-based AC Immune has amended its license and collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease and other neurodegenerative diseases, with IND-enabling studies set to commence in the first half of 2026.

AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy

15 April 2026

Four life sciences projects were recognized at BIND – BioInnovation Day 2026, held at CHUV Lausanne on 1 April 2026, as the region's flagship academic innovation showcase drew 340 participants from academia, healthcare, industry, and investment.

BIND 2026 highlights Western Switzerland’s life sciences innovation pipeline

14 April 2026

Global in vitro diagnostics leader bioMérieux has invested over CHF 1 million in Geneva-based scale-up Plair, whose RAPID-C+ system is setting a new standard for real-time viable particle monitoring in pharmaceutical cleanrooms.

bioMérieux invests in Plair to advance environmental monitoring in pharma

30 March 2026

Santa Catarina Day was recently hosted in Bern, welcoming a delegation from the Brazilian state of Santa Catarina for a dedicated program focused on innovation, industrial cooperation, and economic development.

Santa Catarina Day in Bern highlights innovation and industrial cooperation

11 February 2026

Geneva-based biotech start-up FluoSphera has raised CHF 1.15 million to expand its human-relevant preclinical testing platform, supporting the shift toward more predictive and non-animal drug development models.

FluoSphera raises CHF 1.15 million to scale human-based preclinical drug testing

19 January 2026

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (December 2025)

24 December 2025

The FIT has awarded three Tech Seed loans of CHF 100,000 each to early-stage start-ups CCRAFT, Databaum and Lemna Bio.

FIT backs three start-ups to advance photonics, agritech and AI-driven drug discovery

23 December 2025

Takeda has opened a new CHF 200 million biotechnology facility in Neuchâtel to expand aseptic filling capacity for rare disease therapies.

Takeda inaugurates CHF 200 million biotechnology facility in Neuchâtel

1 December 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (October 2025)

29 October 2025

UCB is investing more than CHF 100 million in its Bulle site to boost capacity, create new jobs, and strengthen sustainable production.

UCB invests over CHF 100 million to expand its biopharmaceutical site in Bulle

7 October 2025

1 2 3 4 5 … 16